Day One Biopharmaceuticals, Inc.: auditor change — Day One Biopharma dismisses EY as auditor, appoints PwC effective Nov 10, 2023

Day One Biopharmaceuticals, Inc.

Audit Committee dismissed EY on Nov 10, 2023; no disagreements or reportable events in prior periods.
PwC appointed as independent registered public accounting firm for fiscal year ending Dec 31, 2023.
EY's reports for FY2021 and FY2022 were unqualified and contained no adverse opinions.
Neither the company nor anyone on its behalf consulted PwC on accounting matters before engagement.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Day One Biopharmaceuticals, Inc. engaged PricewaterhouseCoopers LLP as its auditor.

Action: engagement
Auditor: PricewaterhouseCoopers LLP

Exact text from the filing

On November 10, 2023, the Audit Committee approved the engagement of PricewaterhouseCoopers LLP ("PwC") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Day One Biopharmaceuticals, Inc. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: PricewaterhouseCoopers LLP

Exact text from the filing

dismissed Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001193125-23-277887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.